Tomita, Yuji
Watanabe, Eri
Shimizu, Masumi
Negishi, Yasuyuki
Kondo, Yukihiro
Takahashi, Hidemi http://orcid.org/0000-0003-3283-0845
Funding for this research was provided by:
Grants from the Ministry of Education, Science, Sport, and Culture, from the Ministry of Health and Labor and Welfare, Japan (25461715, 16K09262)
Article History
Received: 26 September 2018
Accepted: 13 September 2019
First Online: 17 September 2019
Compliance with ethical standards
:
: The authors declare no potential conflicts of interest.
: All experiments were performed under a protocol approved by the Institutional Review Board of Nippon Medical School, Tokyo, Japan (approval number 29-08). All blood samples were used for research purposes.
: All experiments were performed after obtaining written consent from healthy donors to use their blood samples. T24-HLA-matched PBMCs (HLA-A1<sup>+</sup> and HLA-A3<sup>+</sup>) were purchased from the CTL ePBMC bank (Cleveland, OH, USA).
: Human urinary bladder carcinoma T24 cells and human erythromyeloblastoid leukemia K562 cells were purchased from American Type Culture Collection (Manassas, VA, USA). The phenotype of these cells was checked and did not change over time.